Innovations in Prostate Cancer Management: Taking a Personalized Approach to Optimal Treatment

Innovations in Prostate Cancer Management: Taking a Personalized Approach to Optimal Treatment is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Prostate cancer is the most diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 191,930 new cases diagnosed in 2021. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. About 40 percent of these patients have prostate cancer which is also associated with a rising prostate-specific antigen (PSA) level that has not spread to other parts of the body. The danger that can occur, if not caught early, is that 33% of those men could have cancer spread to other parts of the body.,Patients with all stages of prostate cancer have many treatment options available to them, from front-line therapy to second-line therapy and beyond with both immunotherapy and chemotherapy as current options. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with prostate cancer have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer, identifying patients who have prostate cancer and preventing undertreatment. This marker is used for early diagnosis and monitoring for disease recurrence. PSA is the most common biochemical marker for prostate cancer and is used as a screening tool, although it remains prostate-specific and not necessarily prostate cancer-specific.,Upon completion of this activity, participants will be able to:,• Implement guideline-recommended management strategies for patients with castration-resistant prostate cancer (CPRC)|,• Assess the predictive biomarkers, clinical efficacy, and safety of current and novel treatments for prostate cancer treatment,• Analyze recent clinical evidence and data to inform personalized treatment strategies for patients with CPRC,• Explore the current and potential future clinical practice implications of PARP inhibitors in prostate cancer, including patient selection and personalized treatment approaches,• Implement strategies to overcome challenges in patients with CRPC, including adherence, adverse events, and effective physician-patient communication strategies,• Examine the clinical pathways and multidisciplinary initiatives for optimal cost management and improved outcomes in prostate cancer